Bio-Techne

TECH

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems (Research and Diagnostic Systems Inc.), Novus Biologicals, Tocris Bioscience, ProteinSimple, Exosome Diagnostics, BiosPacific, Cliniqa, Advanced Cell Diagnostics, RNA Medical, Bionostics, and Boston Biochem. The company's products are used in both clinical and research contexts. The company was co-founded as a "hematology controls developer" by Dr. Roger C. Lucas, who presently serves as its Chief Scientific Advisor.Bio-Techne is listed on the NASDAQ under the ticker symbol TECH. Writing for Forbes from an investor's perspective, John Reese praised the management team saying it "...appears to be doing a solid job...", a sentiment echoed by Philip van Doorn, writing for Dow Jones MarketWatch.

Bio-Techne has been a target of short sellers for a while. The current short interest of 3.76% is significantly below the average of the last 12 months (6.93%).